Breast Cancer Clinical Trial
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Summary
This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas.
The study will have three parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors.
Eligibility Criteria
Monotherapy Inclusion Criteria (Parts A and B)
Histologically- or cytologically-confirmed advanced or metastatic malignancy, defined as:
One of the following tumor types:
Unresectable locally-advanced or metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal (GE) junction carcinoma, cutaneous melanoma, head and neck squamous cell carcinoma (HNSCC), bladder cancer, cervical cancer, ovarian cancer, or triple negative breast cancer (TNBC)
Lymphomas, including:
cHL
Diffuse large B-cell lymphoma (DLBCL)
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)
Lymphoma: Participants should have disease progression on or after treatment with standard therapies expected to provide benefit in the judgement of the investigator.
cHL: Participants must have received at least 3 prior systemic therapies. Participants should have had disease recurrence or progression following brentuximab vedotin therapy or have been ineligible to receive brentuximab vedotin. Participants who have not received autologous stem cell transplant (SCT) must have refused or been deemed ineligible. Participants should have received or not be eligible to have received an anti-PD-1 agent.
DLBCL: Participants must have received at least 2 prior systemic chemo-immunotherapy regimens, including an anti-CD20 agent and combination chemotherapy. Unless clinically contraindicated, participants should have had disease that has relapsed after or be refractory to intensive salvage chemotherapy, including autologous SCT.
PTCL-NOS: Participants must have had at least 1 prior systemic therapy. Participants must have received or have been ineligible to receive the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy. Participants with CD30-positive disease must have received or be ineligible to receive brentuximab vedotin. Participants must have also received intensive salvage therapy (defined as combination chemotherapy ± autologous SCT) unless they refused or were deemed ineligible.
Measurable disease defined as:
Solid tumors: Measurable disease according to RECIST V1.1
Lymphomas: Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and measurable disease of ≥15 mm in the greatest transverse diameter by computed tomography (CT) scan, as assessed by the site radiologist.
A representative archival tumor tissue sample should be available as follows: Participants must provide archived tumor tissue, if available, from the most recent biopsy (less than or equal to [≤] 12 months from screening). If archived tissue is not available, a fresh baseline tumor biopsy will be requested for any participant enrolled in Part B whose tumors are considered accessible and appropriate in the opinion of the investigator.
ECOG Performance Status score of 0 or 1
Combination Inclusion Criteria (Part C)
ECOG Performance Status score of 0 or 1
NSCLC: histological or cytological confirmed metastatic disease. Participants must have received no prior anti-PD-1/PD-L1 therapy allowed.
HNSCC: histological or cytological confirmed metastatic disease. Participants must have received no prior exposure to anti-PD-1/PD-L1 therapy.
Cutaneous Melanoma: histological or cytological confirmed metastatic disease. Participants must not have received anti-PD-1/PD-L1 targeted therapy.
Measurable disease by CT or magnetic resonance imaging (MRI) as defined by RECIST V1.1
Participants must provide archival tumor tissue from the most recent biopsy (≤12 months from screening). If archival tissue is not available, a fresh baseline tumor biopsy that has not been previously irradiated is required for any participant whose tumors are considered accessible and appropriate in the opinion of the investigator.
Combination Inclusion Criteria (Part D)
Histologically- or cytologically-confirmed advanced stage cHL
cHL patients that have failed standard of care for R/R disease including prior treatment with BV.
FDG PET emission tomography avid and bidimensional measurable disease of at least 1.5 cm in longest axis as documented by radiographic technique
ECOG performance status of ≤ 2
Participants are required to have tumor tissue, if available, from the most recent biopsy (≤12 months from screening) prior to start of study treatment. If archival tissue is not available, a fresh screening tumor biopsy is required for any participant whose tumors are considered accessible and appropriate in the opinion of the investigator.
Monotherapy Exclusion Criteria (Parts A and B)
History of another malignancy within 2 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment that has not been completed before the first dose of study drug within the timeframe as follows:
Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeks
Palliative radiotherapy (≤2 weeks of radiotherapy to non-central nervous system [CNS] disease): ≤7 days prior to start of SEA-TGT
Immune-checkpoint inhibitors: 4 weeks
Monoclonal antibodies, antibody-drug conjugates (ADC), or radioimmunoconjugates: 4 weeks (2 weeks with documented disease progression)
T-cell or other cell-based therapies: 12 weeks
Known CNS metastases
Participants with a history of CNS metastases are allowed if they have undergone treatment for the CNS disease, symptoms have resolved, and steroids have been discontinued.
Leptomeningeal involvement by malignant disease is excluded regardless of prior treatment.
Previous allogeneic stem cell transplant (SCT). Participants with prior autologous SCT may be eligible if they are >100 days from autologous SCT and fulfill all other inclusion criteria.
Prior use of any anti-TIGIT mAb.
Participants with a condition requiring systemic treatment with either corticosteroids (greater than [>]10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids and adrenal replacement steroid doses >10 mg daily prednisone or equivalents are permitted in the absence of active immune disease.
Known hypersensitivity to any excipient contained in the drug formulation of SEA-TGT
Combination Exclusion Criteria (Part C)
History of another malignancy within 2 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
Active, non-infectious pneumonitis, pulmonary fibrosis, or known history of immune mediated pneumonitis.
Previous therapy with an anti-PD-1 or anti-PD-L1 inhibitor.
Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment that has not been completed before the first dose of study drug within the timeframe as follows:
Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeks
Palliative radiotherapy (≤2 weeks of radiotherapy to non-CNS disease): ≤7 days prior to start of SEA-TGT.
Immune-checkpoint inhibitors: 4 weeks
Monoclonal antibodies, ADC, or radioimmunoconjugates: 4 weeks (2 weeks with documented disease progression)
T-cell or other cell-based therapies: 12 weeks
Known active CNS metastases.
Participants with a history of CNS metastases are allowed if they have undergone treatment for the CNS disease, symptoms have resolved, and steroids have been discontinued.
Leptomeningeal involvement by malignant disease is excluded regardless of prior treatment.
Known hypersensitivity to any excipient contained in the drug formulation of SEA-TGT or sasanlimab
Participants with active known or suspected autoimmune disease or significant autoimmune-related toxicity from prior immuno-oncology-based therapy (prior autoimmune colitis, pneumonitis, transaminitis); Participants with vitiligo, controlled type 1 diabetes mellitus, residual hypothyroidism requiring hormone replacement, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
History of interstitial lung disease
Participants with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids and adrenal replacement steroid doses >10 mg daily prednisone or equivalents are permitted in the absence of active immune disease.
Prior use of any anti-TIGIT mAb
Combination Exclusion Criteria (Part D)
History of another malignancy within 2 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment that has not been completed before the first dose of study drug within the timeframe as follows:
Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeks
Palliative radiotherapy (≤2 weeks of radiotherapy to CNS disease): ≤7 days prior to start of SEA-TGT
Immune-checkpoint inhibitors: 4 weeks
Monoclonal antibodies, ADC (except brentuximab vedotin), or radioimmunoconjugates: 4 weeks (2 weeks with documented disease progression)
T-cell or other cell-based therapies: 12 weeks
Known active CNS involvement by lymphoma
Previous allogeneic SCT. Participants with prior autologous SCT may be eligible if they are >100 days from autologous SCT and fulfill all other inclusion criteria.
Prior use of any anti-TIGIT mAb.
Participants with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids and adrenal replacement steroid doses >10 mg daily prednisone or equivalents are permitted in the absence of active immune disease.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 34 Locations for this study
Birmingham Alabama, 35249, United States More Info
Principal Investigator
Tucson Arizona, 85710, United States More Info
Principal Investigator
Duarte California, 91010, United States More Info
Principal Investigator
Los Angeles California, 90027, United States More Info
Principal Investigator
San Francisco California, 94134, United States More Info
Principal Investigator
New Haven Connecticut, 06520, United States More Info
Principal Investigator
Baltimore Maryland, 21287, United States More Info
Principal Investigator
Rockville Maryland, 20850, United States More Info
Principal Investigator
Ann Arbor Michigan, 48109, United States More Info
Principal Investigator
Minneapolis Minnesota, 55404, United States More Info
Principal Investigator
Rochester Minnesota, 55905, United States More Info
Principal Investigator
Jackson Mississippi, 39216, United States More Info
Principal Investigator
New York New York, 10021, United States
New York New York, 10065, United States More Info
Principal Investigator
Winston-Salem North Carolina, 27157, United States More Info
Principal Investigator
Cincinnati Ohio, 45219, United States More Info
Principal Investigator
Portland Oregon, 97213, United States
Pittsburgh Pennsylvania, 15232, United States More Info
Principal Investigator
Nashville Tennessee, 37204, United States
Austin Texas, 78705, United States More Info
Principal Investigator
Dallas Texas, 75246, United States More Info
Principal Investigator
Houston Texas, 77030, United States More Info
Principal Investigator
Tyler Texas, 75702, United States More Info
Principal Investigator
Blacksburg Virginia, 24060, United States More Info
Principal Investigator
Fairfax Virginia, 22031, United States More Info
Principal Investigator
Madison Wisconsin, 53792, United States More Info
Principal Investigator
Edmonton Alberta, T6G 1, Canada More Info
Principal Investigator
Toronto Other, M5G 2, Canada More Info
Principal Investigator
Villejuif Cedex Other, 94805, France More Info
Principal Investigator
Milano Other, 20141, Italy More Info
Principal Investigator
Barcelona Other, 08035, Spain More Info
Principal Investigator
Madrid Other, 28050, Spain More Info
Principal Investigator
London Other, W1G 6, United Kingdom More Info
Principal Investigator
Sutton Other, SM2 5, United Kingdom More Info
Principal Investigator
How clear is this clinincal trial information?